bristol-myers glp-1 receptor agonist products GLP1 Agonists—Effects beyond Obesity and Diabetes GLP-1 Agonists: A Comprehensive Overview

FDA labeling for these medications notes that delayed gastric emptying may affect the absorption of concomitantly administered oral medications and that they are not recommended for use in patients with severe gastroparesis

Clin Rheumatol

According to the World Health Organization (WHO), over 422 million people globally live with diabetes, while obesity has nearly tripled since 1975, with more than 1 billion individuals affected, significantly increasing demand for effective GLP-1-based therapeutic interventions worldwide

This article is written for a general adult consumer audience and intends statements to be interpreted as a reasonable consumer would interpret them in context

Standards of Care in Diabetes 2024

Acute pancreatitis and diabetes mellitus: a review